Pulmatrix, Inc. (NASDAQ:PULM) Short Interest Update

Pulmatrix, Inc. (NASDAQ:PULM) saw a significant decrease in short interest during the month of February. As of February 27th, there was short interest totaling 2,779 shares, a decrease of 35.3% from the February 12th total of 4,293 shares. Based on an average daily volume of 18,863 shares, the days-to-cover ratio is currently 0.1 days. Based on an average daily volume of 18,863 shares, the days-to-cover ratio is currently 0.1 days.

Institutional Investors Weigh In On Pulmatrix

Several hedge funds have recently modified their holdings of the company. SBI Securities Co. Ltd. grew its position in shares of Pulmatrix by 15.7% during the 2nd quarter. SBI Securities Co. Ltd. now owns 60,565 shares of the biotechnology company’s stock valued at $418,000 after acquiring an additional 8,208 shares during the period. Dimensional Fund Advisors LP acquired a new position in Pulmatrix in the 3rd quarter worth about $52,000. Finally, DRW Securities LLC purchased a new position in Pulmatrix during the fourth quarter worth approximately $46,000. 11.84% of the stock is owned by hedge funds and other institutional investors.

Pulmatrix Price Performance

Shares of NASDAQ PULM traded down $0.05 during midday trading on Friday, reaching $2.11. 10,821 shares of the stock were exchanged, compared to its average volume of 52,620. The firm has a 50-day simple moving average of $2.49 and a two-hundred day simple moving average of $3.75. Pulmatrix has a twelve month low of $1.63 and a twelve month high of $9.37.

Pulmatrix (NASDAQ:PULM) last posted its earnings results on Thursday, February 26th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Pulmatrix in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Pulmatrix has a consensus rating of “Sell”.

Pulmatrix Company Profile

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).